Scholar Rock Holding (SRRK) Interest Expenses (2024 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Interest Expenses of $2.4 million for Q1 2026, up 15.46% year-over-year from $2.1 million in Q1 2025, and down 17.06% quarter-over-quarter from $2.9 million in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Interest Expenses (2024 - 2026) Analysis & Trends
Scholar Rock Holding's Interest Expenses history runs 10 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 15.46% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $8.9 million (up 20.24% YoY), while the FY2025 annual figure was $185.5 million, down 36.69% from the prior year.
- Interest Expenses for Q1 2026 stood at $2.4 million, down from $2.9 million in the prior quarter.
- The five-year high for Interest Expenses was $159.6 million in Q3 2025, with the low at $748000.0 in Q2 2022.
- The 5-year median for Interest Expenses is $2.4 million (2026), against an average of $20.6 million.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses slumped 98.4% in 2022, then soared 5280.62% in 2025.
- Scholar Rock Holding's Interest Expenses stood at $1.7 million in 2022, then grew by 19.6% to $2.0 million in 2023, then slipped by 19.1% to $1.6 million in 2024, then soared by 76.89% to $2.9 million in 2025, then dropped by 17.06% to $2.4 million in 2026.
- Business Quant data shows SRRK's Interest Expenses at $2.4 million in Q1 2026, $2.9 million in Q4 2025, and $159.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Scholar Rock Holding | 7.25 Bn | 7.25 Bn | - | 4.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.52 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Dec 31, 2025 | 2.53 Mn |
| Sep 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.82 Mn |
| Dec 31, 2024 | 1.65 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 1.72 Mn |
| Mar 31, 2024 | 1.73 Mn |